Header Logo

Connection

Jeffrey Kordower to Disease Models, Animal

Back to Details
This is a "connection" page, showing publications Jeffrey Kordower has written about Disease Models, Animal.
Jeffrey Kordower
Connection Strength
5.368
Disease Models, Animal
  1. Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease. Neurobiol Dis. 2021 01; 148:105184.
    View in: PubMed
    Score: 0.614
  2. Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates. Acta Neuropathol Commun. 2017 06 16; 5(1):47.
    View in: PubMed
    Score: 0.484
  3. a-Synuclein nonhuman primate models of Parkinson's disease. J Neural Transm (Vienna). 2018 03; 125(3):385-400.
    View in: PubMed
    Score: 0.479
  4. Alpha-synuclein propagation: New insights from animal models. Mov Disord. 2016 Feb; 31(2):161-8.
    View in: PubMed
    Score: 0.428
  5. Modeling Parkinson's disease. Ann Neurol. 2009 Oct; 66(4):432-6.
    View in: PubMed
    Score: 0.284
  6. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord. 2007 Jun 15; 22(8):1124-32.
    View in: PubMed
    Score: 0.242
  7. Animal models of Huntington's disease. ILAR J. 2007; 48(4):356-73.
    View in: PubMed
    Score: 0.235
  8. Neural repair strategies for Parkinson's disease: insights from primate models. Cell Transplant. 2006; 15(3):251-65.
    View in: PubMed
    Score: 0.219
  9. A novel tau-based rhesus monkey model of Alzheimer's pathogenesis. Alzheimers Dement. 2021 06; 17(6):933-945.
    View in: PubMed
    Score: 0.157
  10. Disease Modification for Parkinson's Disease: Axonal Regeneration and Trophic Factors. Mov Disord. 2018 05; 33(5):678-683.
    View in: PubMed
    Score: 0.128
  11. Disease Modification Through Trophic Factor Delivery. Methods Mol Biol. 2018; 1780:525-547.
    View in: PubMed
    Score: 0.126
  12. Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol. 2017 12; 298(Pt B):225-235.
    View in: PubMed
    Score: 0.124
  13. Cryopreservation Maintains Functionality of Human iPSC Dopamine Neurons and Rescues Parkinsonian Phenotypes In?Vivo. Stem Cell Reports. 2017 07 11; 9(1):149-161.
    View in: PubMed
    Score: 0.121
  14. Alterations in Activity-Dependent Neuroprotective Protein in Sporadic and Experimental Parkinson's Disease. J Parkinsons Dis. 2016; 6(1):77-97.
    View in: PubMed
    Score: 0.109
  15. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Mov Disord. 2014 Jul; 29(8):999-1009.
    View in: PubMed
    Score: 0.094
  16. Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease. Sci Rep. 2013; 3:2157.
    View in: PubMed
    Score: 0.089
  17. Introduction: gene therapy has gone from a pipe dream to clinical reality. Neurobiol Dis. 2012 Nov; 48(2):151-2.
    View in: PubMed
    Score: 0.086
  18. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord. 2011 Jan; 26(1):27-36.
    View in: PubMed
    Score: 0.077
  19. a-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease. Neurobiol Dis. 2011 Jan; 41(1):71-82.
    View in: PubMed
    Score: 0.076
  20. Neurotrophic factor therapy for Parkinson's disease. Prog Brain Res. 2010; 184:237-64.
    View in: PubMed
    Score: 0.072
  21. Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiol Dis. 2009 Nov; 36(2):303-11.
    View in: PubMed
    Score: 0.070
  22. Injectable hydrogels providing sustained delivery of vascular endothelial growth factor are neuroprotective in a rat model of Huntington's disease. Neurotox Res. 2010 Jan; 17(1):66-74.
    View in: PubMed
    Score: 0.070
  23. Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. Neurobiol Dis. 2009 Apr; 34(1):40-50.
    View in: PubMed
    Score: 0.067
  24. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease. Neurobiol Dis. 2007 May; 26(2):375-84.
    View in: PubMed
    Score: 0.059
  25. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol. 2006 Dec; 60(6):706-15.
    View in: PubMed
    Score: 0.058
  26. Extensive neuroprotection by choroid plexus transplants in excitotoxin lesioned monkeys. Neurobiol Dis. 2006 Aug; 23(2):471-80.
    View in: PubMed
    Score: 0.056
  27. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9345-50.
    View in: PubMed
    Score: 0.056
  28. Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism. Exp Neurol. 2005 Feb; 191 Suppl 1:S60-7.
    View in: PubMed
    Score: 0.051
  29. Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. J Comp Neurol. 2004 Jul 19; 475(2):211-9.
    View in: PubMed
    Score: 0.049
  30. Primate models of Parkinson's disease. Exp Neurol. 2003 Oct; 183(2):258-62.
    View in: PubMed
    Score: 0.047
  31. Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp Neurol. 2003 Jun; 181(2):213-23.
    View in: PubMed
    Score: 0.046
  32. In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease. Ann Neurol. 2003; 53 Suppl 3:S120-32; discussion S132-4.
    View in: PubMed
    Score: 0.044
  33. Inflammation in Experimental Models of a-Synucleinopathies. Mov Disord. 2021 01; 36(1):37-49.
    View in: PubMed
    Score: 0.038
  34. Anti-a-synuclein ASO delivered to monoamine neurons prevents a-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys. EBioMedicine. 2020 Sep; 59:102944.
    View in: PubMed
    Score: 0.038
  35. T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease. Acta Neuropathol. 2020 05; 139(5):855-874.
    View in: PubMed
    Score: 0.036
  36. Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease. Neurobiol Dis. 2020 02; 135:104352.
    View in: PubMed
    Score: 0.034
  37. Role of TLR4 in the gut-brain axis in Parkinson's disease: a translational study from men to mice. Gut. 2019 05; 68(5):829-843.
    View in: PubMed
    Score: 0.034
  38. Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease. Sci Transl Med. 2016 12 07; 8(368):368ra174.
    View in: PubMed
    Score: 0.029
  39. Neutralization of RANTES and Eotaxin Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson Disease. J Biol Chem. 2016 07 15; 291(29):15267-81.
    View in: PubMed
    Score: 0.028
  40. PGC-1a Promoter Methylation in Parkinson's Disease. PLoS One. 2015; 10(8):e0134087.
    View in: PubMed
    Score: 0.027
  41. Attenuation of microglial RANTES by NEMO-binding domain peptide inhibits the infiltration of CD8(+) T cells in the nigra of hemiparkinsonian monkey. Neuroscience. 2015 Aug 27; 302:36-46.
    View in: PubMed
    Score: 0.026
  42. Neonatal immune-tolerance in mice does not prevent xenograft rejection. Exp Neurol. 2014 Apr; 254:90-8.
    View in: PubMed
    Score: 0.024
  43. Prenatal exposure to MDMA alters noradrenergic neurodevelopment in the rat. Neurotoxicol Teratol. 2012 Jan-Feb; 34(1):206-13.
    View in: PubMed
    Score: 0.020
  44. Association of early experience with neurodegeneration in aged primates. Neurobiol Aging. 2011 Jan; 32(1):151-6.
    View in: PubMed
    Score: 0.017
  45. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A. 2007 Nov 20; 104(47):18754-9.
    View in: PubMed
    Score: 0.016
  46. Deep brain stimulation for treatment of obesity in rats. J Neurosurg. 2007 Oct; 107(4):809-13.
    View in: PubMed
    Score: 0.015
  47. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis. 2007 Jul; 27(1):67-76.
    View in: PubMed
    Score: 0.015
  48. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol. 2006 Aug; 60(2):260-4.
    View in: PubMed
    Score: 0.014
  49. Survival and early differentiation of human neural stem cells transplanted in a nonhuman primate model of stroke. J Neurosurg. 2006 Jul; 105(1):96-102.
    View in: PubMed
    Score: 0.014
  50. Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol Dis. 2006 Jan; 21(1):165-80.
    View in: PubMed
    Score: 0.013
  51. Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration. J Pharmacol Exp Ther. 2003 Jul; 306(1):218-28.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.